ORBi: Detailled Reference

Article (Scientific journals)

Estetrol and Mammary Gland: Friends or Foes?

Gallez, Anne; Dias Da Silva, Isabelle; Wuidar, Vincent et al.

2021 • In Journal of Mammary Gland Biology and Neoplasia, 26 (3), p. 297 - 308

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/291232

DOI
10.1007/s10911-021-09497-0

PubMed
34463898

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Gallez A et al, 2021.pdf

Author postprint (1.6 MB)

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Breast cancer; Contraception; Estetrol; Estrogen receptor; Mammary gland; Menopause; Breast Neoplasms; Contraceptives, Oral, Hormonal; Female; Hormone Replacement Therapy; Humans; Mammary Glands, Human; Oncology; Cancer Research

Abstract :

[en] Estrogens have pleiotropic effects on many reproductive and non-reproductive tissues and organs including the mammary gland, uterus, ovaries, vagina, and endothelium. Estrogen receptor α functions as the principal mediator of estrogenic action in most of these tissues. Estetrol (E4) is a native fetal estrogen with selective tissue actions that is currently approved for use as the estrogen component in a combined oral contraceptive and is being developed as a menopause hormone therapy (MHT, also known as hormone replacement therapy). However, exogenous hormonal treatments, in particular MHTs, have been shown to promote the growth of preexisting breast cancers and are associated with a variable risk of breast cancer depending on the treatment modality. Therefore, evaluating the safety of E4-based formulations on the breast forms a crucial part of the clinical development process. This review highlights preclinical and clinical studies that have assessed the effects of E4 and E4-progestogen combinations on the mammary gland and breast cancer, focusing in particular on the estrogenic and anti-estrogenic properties of E4. We discuss the potential advantages of E4 over current available estrogen-formulations as a contraceptive and for the treatment of symptoms due to menopause. We also consider the potential of E4 for the treatment of endocrine-resistant breast cancer.

Disciplines :

Oncology

Author, co-author :

Gallez, Anne ; Université de Liège - ULiège > GIGA > GIGA Cancer - Tumours and development biology

Dias Da Silva, Isabelle ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques

Wuidar, Vincent ; Université de Liège - ULiège > GIGA

Foidart, Jean-Michel ; Université de Liège - ULiège > Département des sciences cliniques

Pequeux, Christel ; Université de Liège - ULiège > GIGA > GIGA Cancer - Tumours and development biology

Language :

English

Title :

Estetrol and Mammary Gland: Friends or Foes?

Publication date :

September 2021

Journal title :

Journal of Mammary Gland Biology and Neoplasia

ISSN :

1083-3021

eISSN :

1573-7039

Publisher :

Springer

Volume :

26

Issue :

3

Pages :

297 - 308

Peer reviewed :

Peer Reviewed verified by ORBi

Funding text :

The authors are funded by the University of Liège, the Fondation Léon Fredericq, the Belgium National Fund for Scientific Research (FNRS) and the Télévie.

Available on ORBi :

since 24 May 2022

Statistics

Number of views

121 (1 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

14

Scopus citations^®
without self-citations

14

OpenCitations

3

Bibliography

Vasquez YM. Estrogen-regulated transcription: Mammary gland and uterus. Steroids. 2018;133:82–6.
Hamilton KJ, Hewitt SC, Arao Y, Korach KS. Estrogen hormone biology. Curr Top Dev Biol. 2017;125:109–46.
Brisken C, Ataca D. Endocrine hormones and local signals during the development of the mouse mammary gland. Wiley Interdiscip Rev Dev Biol. 2015;4:181–95.
Baudry M, Bi X, Aguirre C. Progesterone-estrogen interactions in synaptic plasticity and neuroprotection. Neuroscience. 2013;239:280–94.
Krassas GE, Papadopoulou P. Oestrogen action on bone cells. J Musculoskel Neuron Interact. 2001;2:143–51.
Meyer MR, Clegg DJ, Prossnitz ER, Barton M. Obesity, insulin resistance and diabetes: sex differences and role of oestrogen receptors. Acta Physiol. 2011;203:259–69.
Handgraaf S, Riant E, Fabre A, Waget A, Burcelin R, Lière P, et al. Prevention of obesity and insulin resistance by estrogens requires ERα activation function-2 (ERαAF-2), whereas ERαAF-1 is dispensable. Diabetes. 2013;62:4098–108.
Thornton MJ. Estrogens and aging skin. Dermatoendocrinol. 2013;5:264–70.
Toutain CE, Brouchet L, Raymond-Letron I, Vicendo P, Bergès H, Favre J, et al. Prevention of skin flap necrosis by estradiol involves reperfusion of a protected vascular network. Circ Res. 2009;104:245–54.
Ansar Ahmed S, Penhale WJ, Talal N. Sex hormones, immune responses, and autoimmune diseases. Mechanisms of sex hormone action. Am J Pathol. 1985;121:531–51.
Pavlidou E, et al. Menopause hormonal treatments in 2016. Med Rev from Switz. 2016;12:1805–10.
Pinkerton JAV, Aguirre FS, Blake J, Cosman F, Hodis H, Hoffstetter S, et al. The 2017 hormone therapy position statement of the North American Menopause Society. Menopause. 2017;24:728–53.
Tanos T, Rojo LJ, Echeverria P, Brisken C. ER and PR signaling nodes during mammary gland development. Breast Cancer Res. 2012;14:1–12.
Trémollieres F. Oral combined contraception: Is there any difference between ethinyl-estradiol and estradiol?. Gynecol Obstet Fertil. 2012;40:109–15.
Collaborative Group on Hormonal Factors in Breast. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347:1713–27.
Mørch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard Ø. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med. 2017;377:2228–39.
Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners’ Oral Contraception Study. Am J Obstet Gynecol. 2017;216:580.e1-580.e9.
Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner’s oral contraception study. Br Med J. 2007;335:1–8.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial. J Am Med Assoc. 2002;288:321–33.
Wysowski DK, Governale LA. Use of menopausal hormones in the United States, 1992 through June, 2003. Pharmacoepidemiol Drug Saf. 2004;14:171–6.
Banks E, Beral V, Bull D, Reeves G, Austoker J, English R, et al. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet Lancet Publishing Group. 2003;362:419–27.
Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study. Breast Cancer Res Treat. 2008;107:103–11.
Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol. 2009;113:65–73.
Bakken K, Fournier A, Lund E, Waaseth M, Dumeaux V, Clavel-Chapelon F, et al. Menopausal hormone therapy and breast cancer risk: Impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2011;128:144–56.
Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer Int J Cancer. 2005;114:448–54.
Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2012;7:CD004143.
Holm M, Olsen A, Au Yeung S, Overvad K, Lidegaard Ø, Kroman N, et al. Pattern of mortality after menopausal hormone therapy: long-term follow up in a population-based cohort. BJOG An Int J Obstet Gynaecol. 2019;126:55–63.
Beral V, Peto R, Pirie K. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet Lancet Publishing Group. 2019;394:1159–68.
Beral V, Bull D, Doll R, Key T, Peto R, Reeves G, et al. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. The Lancet. 1997;350:1047–59.
Hagen AA, Barr M, Diczfalusy E. Metabolism of 17-Beta-estradiol-4-14-C in early infancy. Acta Endocrinol (Copenh). 1965;49:207–20.
Cantineau R, Kremers P, De Graeve J, Gielen JE, Lambotte R. 15- and 16-hydroxylations of androgens and estrogens in the human fetal liver: A critical step in estetrol biosynthesis. J Steroid Biochem. 1985;22:195–201.
Holinka CF, Diczfalusy E, Coelingh Bennink HJT. Estetrol: A unique steroid in human pregnancy. Climacteric. 2008;11:1–10.
Coelingh Bennink F, Holinka CF, Visser M, Coelingh Bennink HJT. Maternal and fetal estetrol levels during pregnancy. Climacteric. 2008;11:69–72.
Tulchinsky D, Frigoletto FD, Ryan KJ, Fishman J. Plasma estetrol as an index of fetal well-being. J Clin Endocrinol Metab. 1975;40:560–7.
Holinka CF, Diczfalusy E, Coelingh Bennink HJT. Estetrol: A unique steroid in human pregnancy. J Steroid Biochem Mol Biol Pergamon. 2008;110:138–43.
Visser M, Holinka CF, Coelingh Bennink HJT. First human exposure to exogenous single-dose oral estetrol in early postmenopausal women. Climacteric. 2008;11:31–40.
Coelingh Bennink HJT, Heegaard AM, Visser M, Holinka CF, Christiansen C. Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model. Climacteric Taylor & Francis. 2008;11:2–14.
Visser M, Foidart JM, Coelingh Bennink HJT. In vitro effects of estetrol on receptor binding, drug targets and human liver cell metabolism. Climacteric. 2008;11:64–8.
Fishman J. Fate of 15α-hydroxyestriol-3H in adult man. J Clin Endocrinol Metab. 1970;31:436–8.
Jirku H, Kadner S, Levitz M. Pattern of estetrol conjugation in the human. Steroids Elsevier. 1972;19:519–34.
Abot A, Fontaine C, Buscato M, Solinhac R, Flouriot G, Fabre A, et al. The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor α modulation, uncoupling nuclear and membrane activation. EMBO Mol Med. 2014;6:1328–46.
Billon-Galés A, Fontaine C, Filipe C, Douin-Echinard V, Fouque MJ, Flouriot G, et al. The transactivating function 1 of estrogen receptor α is dispensable for the vasculoprotective actions of 17 β-estradiol. Proc Natl Acad Sci. 2009;106:2053–8.
Billon-Galés A, Krust A, Fontaine C, Abot A, Flouriot G, Toutain C, et al. Activation function 2 (AF2) of estrogen receptor-α is required for the atheroprotective action of estradiol but not to accelerate endothelial healing. Proc Natl Acad Sci U S A. 2011;108:13311–6.
Adlanmerini M, Solinhac R, Abot A, Fabre A, Raymond-Letron I, Guihot AL, et al. Mutation of the palmitoylation site of estrogen receptor a in vivo reveals tissue-specific roles for membrane versus nuclear actions. Proc Natl Acad Sci U S A. 2014;111:E283–90.
Abot A, Fontaine C, Raymond-Letron I, Flouriot G, Adlanmerini M, Buscato M, et al. The AF-1 activation function of estrogen receptor α is necessary and sufficient for uterine epithelial cell proliferation in vivo. Endocrinology Oxford Academic. 2013;154:2222–33.
Arao Y, Hamilton KJ, Ray MK, Scott G, Mishina Y, Korach KS. Estrogen receptor α AF-2 mutation results in antagonist reversal and reveals tissue selective function of estrogen receptor modulators. Proc Natl Acad Sci U S A. 2011;108:14986–91.
Brouchet L, Krust A, Dupont S, Chambon P, Bayard F, Arnal JF. Estradiol accelerates reendothelialization in mouse carotid artery through estrogen receptor-alpha but not estrogen receptor-beta. Circulation. 2001;103:423–8.
Khbouz B, Bournonville C, Court L, Taziaux M, Corona R, Arnal J, et al. Role for the membrane estrogen receptor alpha in the sexual differentiation of the brain. Eur J Neurosci. 2020;52:2627–45.
Pedram A, Razandi M, Lewis M, Hammes S, Levin ER. Membrane-localized estrogen receptor α is required for normal organ development and function. Dev Cell Cell Press. 2014;29:482–90.
Arnal J-F, Lenfant F, Metivier R, Flouriot G, Henrion D, Adlanmerini M, et al. Membrane and nuclear estrogen receptor alpha actions: From tissue specificity to medical implications. Physiol Rev. 2017;97:1045–87.
Arnal JF, Fontaine C, Abot A, Valera MC, Laurell H, Gourdy P, et al. Lessons from the dissection of the activation functions (AF-1 and AF-2) of the estrogen receptor alpha in vivo. Steroids Elsevier. 2013;78:576–82.
Soltysik K, Czekaj P. Membrane estrogen receptors - is it an alternative way of estrogen action?. J Physiol Pharmacol. 2013;64:129–42.
Hilgers RHP, Oparil S, Wouters W, Coelingh Bennink HJT. Vasorelaxing effects of estetrol in rat arteries. J Endocrinol. 2012;215:97–106.
Levine MG, Miodovnik M, Clark KE. Uterine vascular effects of estetrol in nonpregnant ewes. Am J Obstet Gynecol. 1984;148:735–8.
Foidart J, Gaspard U, Péqueux C, Jost M, Gordenne V, Tskitishvili E, et al. Unique vascular benefits of estetrol, a native fetal estrogen with specific actions in tissues (NEST). In: ISGE Series; Brinton R.D., Genazzani A.R., Simoncini T. et al., Sex steroids. Effects on brain, heart and vessels. Int Soc Gynecol Endocrinol. 2019. pp. 169–95.
Pedram A, Razandi M, Kim JK, O’Mahony F, Lee EYHP, Lederer U, et al. Developmental phenotype of a membrane only estrogen receptor α (MOER) mouse. J Biol Chem. 2009;284:3488–95.
Chambliss KL, Wu Q, Oltmann S, Konaniah ES, Umetani M, Korach KS, et al. Non-nuclear estrogen receptor α signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. J Clin Invest. 2010;120:2319–30.
Gérard C, Blacher S, Communal L, Courtin A, Tskitishvili E, Mestdagt M, et al. Estetrol is a weak estrogen antagonizing estradiol-dependent mammary gland proliferation. J Endocrinol BioScientifica Ltd. 2014;224:85–95.
Gérard C, Mestdagt M, Tskitishvili E, Communal L, Gompel A, Silva E, et al. Combined estrogenic and anti-estrogenic properties of estetrol on breast cancer may provide a safe therapeutic window for the treatment of menopausal symptoms. Oncotarget. 2015;6:17621–36.
Gallez A, Blacher S, Maquoi E, Konradowski E, Joiret M, Primac I, et al. Estetrol combined to progestogen for menopause or contraception indication is neutral on breast cancer. Cancers. 2021;13(2486):1–23.
Abderrahman B, Maximov PY, Curpan RF, Hanspal JS, Fan P, Xiong R, Tonetti DA, Thatcher GRJ, Jordan VC. Pharmacology and molecular mechanisms of clinically relevant estrogen estetrol and estrogen mimic BMI-135 for the treatment of endocrine-resistant breast cancer. Mol Pharmacol. 2020;98:364–81.
Visser M, Kloosterboer HJ, Coelingh Bennink HJT. Estetrol prevents and suppresses mammary tumors induced by DMBA in a rat model. Horm Mol Biol Clin Investig. 2012;9:95–103.
Yue W, Verhoeven C, Bernnink HC, Wang JP, Santen RJ. Pro-apoptotic effects of estetrol on long-term estrogen-deprived breast cancer cells and at low doses on hormone-sensitive cells. Breast Cancer Basic Clin Res. 2019;13:1–8.
Singer CF, Bennink HJTC, Natter C, Steurer S, Rudas M, Moinfar F, et al. Antiestrogenic effects of the fetal estrogen estetrol in women with estrogen-receptor positive early breast cancer. Carcinogenesis. 2014;35:2447–51.
Schmidt M, Lenhard H, Hoenig A, Zimmerman Y, Krijgh J, Jansen M, Coelingh Bennink HJT. Tumor suppression, dose-limiting toxicity and wellbeing with the fetal estrogen estetrol in patients with advanced breast cancer. J Cancer Res Clin Oncol. 2021;147:1833–42.
Jozan S, Kreitmann B, Bayard F. Different effects of oestradiol, oestriol, oestetrol and of oestrone on human breast cancer cells (MCF-7) in long term tissue culture. Acta Endocrinol. 1981;98:73–80.
Giretti MS, Guevara MMM, Cecchi E, Mannella P, Palla G, Spina S, et al. Effects of estetrol on migration and invasion in T47-D breast cancer cells through the actin cytoskeleton. Front Endocrinol Frontiers Research Foundation. 2014;5:1–8.
Lippert C, Seeger H, Mueck AO. The effect of endogenous estradiol metabolites on the proliferation of human breast cancer cells. Life Sci. 2003;72:877–83.
Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE, Tarulli GA, et al. Progesterone receptor modulates ERα action in breast cancer. Nature Nature Publishing Group. 2015;523:313–7.
Visser M, Coelingh Bennink HJT. Clinical applications for estetrol. J Steroid Biochem Mol Biol Pergamon. 2009;114:85–9.
Coelingh Bennink HJT, Holinka CF, Diczfalusy E. Estetrol review: profile and potential clinical applications. Climacteric. 2008;11:47–58.
Coelingh Bennink HJT, Skouby S, Bouchard P, Holinka CF. Ovulation inhibition by estetrol in an in vivo model. Contraception. 2008;77:186–90.
Duijkers IJM, Klipping C, Zimmerman Y, Appels N, Jost M, Maillard C, et al. Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: Results of a phase II dose-finding pilot study. Eur J Contracept Reprod Heal Care. 2015;20:476–89.
Apter D, Zimmerman Y, Beekman L, Mawet M, Maillard C, Foidart JM, et al. Bleeding pattern and cycle control with estetrol-containing combined oral contraceptives: Results from a phase II, randomised, dose-finding study (FIESTA). Contraception. 2016;94:366–73.
Apter D, Zimmerman Y, Beekman L, Mawet M, Maillard C, Foidart J-M, et al. Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control. Eur J Contracept Reprod Heal Care. 2017;22:260–7.
Mawet M, Maillard C, Klipping C, Zimmerman Y, Foidart JM, Bennink HJTC. Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives. Eur J Contracept Reprod Heal Care. 2015;20:463–75.
Hammond GL, Hogeveen KN, Visser M, Coelingh Bennink HJT. Estetrol does not bind sex hormone binding globulin or increase its production by human HepG2 cells. Climacteric. 2008;11:41–6.
Valéra M-C, Noirrit-Esclassan E, Dupuis M, Fontaine C, Lenfant F, Briaux A, et al. Effect of estetrol, a selective nuclear estrogen receptor modulator, in mouse models of arterial and venous thrombosis. Mol Cell Endocrinol. 2018;477:132–9.
Kluft C, Zimmerman Y, Mawet M, Klipping C, Duijkers IJM, Neuteboom J, et al. Reduced hemostatic effects with drospirenone-based oral contraceptives containing estetrol vs. ethinyl estradiol. Contraception. 2017;95:140–7.
Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: Mechanisms and clinical consequences. Endocr Rev. 2009;30:465–93.
Mehta J, Kling JM, Manson JE. Risks, benefits, and treatment modalities of menopausal hormone therapy: Current concepts. Front Endocrinol. 2021;12:1–14.
Cui J, Shen Y, Li R. Estrogen synthesis and signaling pathways during aging: From periphery to brain. Trends Mol Med NIH Public Access. 2013;19:197–209.
Al-Safi ZA, Santoro N. Menopausal hormone therapy and menopausal symptoms. Fertil Steril. 2014;101:905–15.
Santoro N, Epperson CN, Mathews SB. Menopausal symptoms and their management. Endocrinol Metab Clin North Am. 2015;44:497–515.
Nelson H, Haney E, Humphrey L, Miller J, Nedrow A, Nicolaidis C, et al. Management of menopause-related symptoms: Summary. Agency Healthc Res Qual. 2005;120:1–10.
Holinka CF, Brincat M, Coelingh Bennink HJT. Preventive effect of oral estetrol in a menopausal hot flush model. Climacteric. 2008;11:15–21.
Ishiwata T, Saito T, Hasegawa H, Yazawa T, Kotani Y, Otokawa M, et al. Changes of body temperature and thermoregulatory responses of freely moving rats during GABAergic pharmacological stimulation to the preoptic area and anterior hypothalamus in several ambient temperatures. Brain Res. 2005;1048:32–40.
Pluchino N, Santoro AN, Casarosa E, Giannini A, Genazzani A, Russo M, et al. Effect of estetrol administration on brain and serum allopregnanolone in intact and ovariectomized rats. J Steroid Biochem Mol Biol. 2014;143:285–90.
Pluchino N, Drakopoulos P, Casarosa E, Freschi L, Petignat P, Yaron M, et al. Effect of estetrol on beta-endorphin level in female rats. Steroids. 2015;95:104–10.
Coelingh Bennink HJT, Verhoeven C, Zimmerman Y, Visser M, Foidart JM, Gemzell-Danielsson K. Clinical effects of the fetal estrogen estetrol in a multiple-rising-dose study in postmenopausal women. Maturitas. 2016;91:93–100.
Gaspard U, Taziaux M, Mawet M, Jost M, Gordenne V, Coelingh Bennink HJT, et al. A multicenter, randomized study to select the minimum effective dose of estetrol (E4) in postmenopausal women (E4Relief). Menopause. 2020;27:848–57.
Benoit T, Valera M-C, Fontaine C, Buscato M, Lenfant F, Raymond-Letron I, et al. Estetrol, a fetal selective estrogen receptor modulator, acts on the vagina of mice through nuclear estrogen receptor α activation. Am J Pathol. 2017;187:2499–507.
Heegaard AM, Holinka CF, Kenemans P, Coelingh Bennink HJT. Estrogenic uterovaginal effects of oral estetrol in the modified Allen-Doisy test. Climacteric. 2008;11:22–8.
Tskitishvili E, Nisolle M, Munaut C, Pequeux C, Gerard C, Noel A, et al. Estetrol attenuates neonatal hypoxic-ischemic brain injury. Exp Neurol. 2014;261:298–307.
Coelingh Bennink HJT, Verhoeven C, Zimmerman Y, Visser M, Foidart J-M, Gemzell-Danielsson K. Pharmacodynamic effects of the fetal estrogen estetrol in postmenopausal women: results from a multiple-rising-dose study. Menopause. 2017;24:677–85.
Buscato M, Davezac M, Zahreddine R, Adlanmerini M, Métivier R, Fillet M, Cobraiville G, Moro C, Foidart J-M, et al. Estetrol prevents western diet–induced obesity and atheroma independently of hepatic estrogen receptor α. Am J Physiol - Endocrinol Metab. 2021;320:E19-29.
Holinka CF, Gurpide E. In vivo effects of estetrol on the immature rat uterus. Biol Reprod Oxford Academic. 1979;20:242–6.
Holinka CF, Bressler RS, Zehr DR, Gurpide E. Comparison of effects of estetrol and tamoxifen with those of estriol and estradiol on the immature rat uterus. Biol Reprod. 1980;22:913–26.
Anderson GL, Limacher M. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The women’s health initiative randomized controlled trial. J Am Med Assoc. 2004;291:1701–12.
Roehm E. A reappraisal of women’s health initiative estrogen-alone trial: Long-term outcomes in women 50–59 years of age. Obstet Gynecol Int. 2015;2015:1–10.
Chlebowski RT, Anderson GL, Aragaki AK, Manson JE, Stefanick ML, Pan K, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women’s health initiative randomized clinical trials. J Am Med Assoc. 2020;324:369–80.
Ellis MJ, Gao F, Dehdashti F, Jeffe DB, Marcom PK, Carey LA, et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: A phase 2 randomized study. J Am Med Assoc. 2009;302:774–80.
Iwase H, Yamamoto Y, Yamamoto-Ibusuki M, Murakami KI, Okumura Y, Tomita S, et al. Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: A prospective study. Br J Cancer. 2013;109:1537–42.
Lønning PE, Taylor PD, Anker G, Iddon J, Wie L, Jørgensen LM, et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat. 2001;67:111–6.
Cagnet S, Ataca D, Sflomos G, Aouad P, Schuepbach-Mallepell S, Hugues H, Krust A, et al. Oestrogen receptor α AF-1 and AF-2 domains have cell population-specific functions in the mammary epithelium. Nat Commun. 2018;9:4723:1–15.
Gagniac L, Rusidzé M, Boudou F, Cagnet S, Adlanmerini M, Jeannot P, Gaide N, Giton F, et al. Membrane expression of the estrogen receptor ERα is required for intercellular communications in the mammary epithelium. Development. 2020;147:1–15.

Similar publications